Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria A Sullivan

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Addictive Behaviors|August 11, 2020
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trialThomas Kosten, Efrat Aharonovich, Narinder Nangia, et al.
The American Journal on Addictions|February 9, 2022
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential settingPaolo Mannelli, Antoine B Douaihy, Sarah C Akerman, et al.
The American Journal on Addictions|April 25, 2015
Baseline characteristics of patients predicting suitability for rapid naltrexone inductionShanthi Mogali, Nabil A Khan, Esther S Drill, et al.
The Clinical Journal of Pain|March 11, 2015
Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young AdultsJohn M Saroyan, Elizabeth A Evans, Andrew Segoshi, et al.
The American Journal on Addictions|March 30, 2018
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategiesAdam Bisaga, Paolo Mannelli, Maria A Sullivan, et al.
Drug and Alcohol Dependence|May 19, 2005
Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implantsGary K Hulse, Robert J Tait, Sandra D Comer, et al.
Journal of Opioid Management|September 10, 2009
Relationship between rate of infusion and reinforcing strength of oxycodone in humansSandra D Comer, Judy B Ashworth, Maria A Sullivan, et al.
Addiction (Abingdon, England)|March 2, 2018
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes RegistryAndrew J Saxon, Sarah C Akerman, Chih-Chin Liu, et al.
Addiction (Abingdon, England)|June 14, 2020
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanismEdward V Nunes, Adam Bisaga, Evgeny Krupitsky, et al.
Journal of Psychoactive Drugs|December 6, 2016
Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use DisorderVerena E Metz, Maria A Sullivan, Jermaine D Jones, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Addictive Behaviors|August 11, 2020
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trialThomas Kosten, Efrat Aharonovich, Narinder Nangia, et al.
The American Journal on Addictions|February 9, 2022
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential settingPaolo Mannelli, Antoine B Douaihy, Sarah C Akerman, et al.
The American Journal on Addictions|April 25, 2015
Baseline characteristics of patients predicting suitability for rapid naltrexone inductionShanthi Mogali, Nabil A Khan, Esther S Drill, et al.
The Clinical Journal of Pain|March 11, 2015
Interviewing and Urine Drug Toxicology Screening in a Pediatric Pain Management Center: An Analysis of Analgesic Nonadherence and Aberrant Behaviors in Adolescents and Young AdultsJohn M Saroyan, Elizabeth A Evans, Andrew Segoshi, et al.
The American Journal on Addictions|March 30, 2018
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategiesAdam Bisaga, Paolo Mannelli, Maria A Sullivan, et al.
Drug and Alcohol Dependence|May 19, 2005
Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implantsGary K Hulse, Robert J Tait, Sandra D Comer, et al.
Journal of Opioid Management|September 10, 2009
Relationship between rate of infusion and reinforcing strength of oxycodone in humansSandra D Comer, Judy B Ashworth, Maria A Sullivan, et al.
Addiction (Abingdon, England)|March 2, 2018
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes RegistryAndrew J Saxon, Sarah C Akerman, Chih-Chin Liu, et al.
Addiction (Abingdon, England)|June 14, 2020
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanismEdward V Nunes, Adam Bisaga, Evgeny Krupitsky, et al.
Journal of Psychoactive Drugs|December 6, 2016
Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use DisorderVerena E Metz, Maria A Sullivan, Jermaine D Jones, et al.
Pageof 9